Spots Global Cancer Trial Database for Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Official Title: Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Study ID: NCT05172700
Interventions
Study Description
Brief Summary: This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Contact Lilly at 1-800-LillyRx (1-800-545-5979)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
